Celldex Therapeutics, Inc. (CLDX) Deep Dive Video

Summary

Celldex offers a catalyst-rich, well-funded bet on barzolvolimab becoming a disease-modifying mast cell therapy that could redefine chronic urticaria treatment.

View CLDX stock page · Read the CLDX research report

Loading the video player…